Can You Take Amlodipine with Spironolactone?
Yes, amlodipine and spironolactone can be safely taken together—this combination is commonly used and well-established in clinical practice for treating hypertension, particularly resistant hypertension. There are no direct pharmacokinetic interactions between these medications, and they work through complementary mechanisms to lower blood pressure 1.
Evidence Supporting This Combination
The 2025 AHA/ACC hypertension guidelines explicitly recognize combination therapy involving calcium channel blockers (like amlodipine) and mineralocorticoid receptor antagonists (like spironolactone) as appropriate treatment strategies 1. While the guidelines list fixed-dose combinations available on the market, they acknowledge that these medications are frequently prescribed together as separate agents.
Multiple clinical studies have directly evaluated this combination:
- A randomized crossover trial in elderly hypertensive patients already on amlodipine and an ARB found that adding spironolactone significantly reduced blood pressure and actually preserved endothelial function better than adding a thiazide diuretic 2
- Another study comparing spironolactone versus amlodipine in diabetic nephropathy patients found both were well-tolerated, with spironolactone showing additional benefits on certain inflammatory markers 3
- A quality-of-life study directly comparing eplerenone (another aldosterone antagonist) to amlodipine found both effectively lowered blood pressure, though eplerenone was better tolerated regarding symptom distress 4
Clinical Context: When This Combination Is Used
Spironolactone is particularly effective as a fourth-line agent in resistant hypertension (defined as uncontrolled blood pressure despite three medications including a diuretic) 1, 5, 6, 7. The typical scenario involves:
- Patient already on amlodipine (or another calcium channel blocker)
- Plus an ACE inhibitor or ARB
- Plus a thiazide-type diuretic
- Blood pressure remains uncontrolled
- Spironolactone 25-50 mg daily is added 1, 5
Critical Safety Monitoring Required
While the combination is safe, you must monitor for hyperkalemia (elevated potassium), especially if the patient is also taking:
The FDA label for spironolactone explicitly warns about this risk 8. Check serum potassium and renal function:
- Before starting spironolactone
- Within 1 week of initiation
- At 1 month
- Then every 3-6 months thereafter
- Whenever ACE inhibitor or ARB doses are adjusted 8
Avoid spironolactone if:
- GFR <45 mL/min 1
- Baseline potassium >5.0 mEq/L
- Patient is on potassium supplements (generally discontinue these when starting spironolactone) 8
Other Monitoring Considerations
From the amlodipine side, watch for:
- Peripheral edema (ankle swelling)—the most common side effect, occurring in 5.6% of men and 14.6% of women 9
- Flushing, dizziness, or palpitations 9
From the spironolactone side, monitor for:
- Gynecomastia (breast enlargement in men)—if this occurs, consider switching to eplerenone 1, 5
- Worsening renal function 1
- Hyperkalemia (as discussed above) 8
Practical Prescribing Algorithm
- Confirm the patient needs both medications (typically resistant hypertension or specific indications like heart failure with reduced ejection fraction for spironolactone)
- Check baseline labs: potassium, creatinine, GFR
- Review all current medications for potassium-raising drugs 8
- Start spironolactone at 25 mg daily if labs are acceptable 1, 5
- Discontinue potassium supplements if present 8
- Recheck potassium and creatinine within 1 week, then at 1 month 8
- Can increase spironolactone to 50 mg daily if blood pressure remains uncontrolled and potassium remains safe 1, 5
Bottom Line
This is a safe, evidence-based combination that is commonly used in clinical practice. The key is appropriate patient selection (avoiding those with significant renal impairment or baseline hyperkalemia) and vigilant monitoring of potassium levels, particularly in the first month of therapy. The combination is explicitly supported by current hypertension guidelines and has been studied in multiple clinical trials without safety concerns regarding drug-drug interactions between these two specific agents 1, 2, 3.